Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Envoy Medical (COCHW) over the last 4 years, with Q3 2025 value amounting to $8.2 million.

  • Envoy Medical's Liabilities and Shareholders Equity fell 1294.03% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.0 million, marking a year-over-year increase of 2164.82%. This contributed to the annual value of $11.5 million for FY2024, which is 3949.95% up from last year.
  • Latest data reveals that Envoy Medical reported Liabilities and Shareholders Equity of $8.2 million as of Q3 2025, which was down 1294.03% from $9.9 million recorded in Q2 2025.
  • Over the past 5 years, Envoy Medical's Liabilities and Shareholders Equity peaked at $427.8 million during Q3 2022, and registered a low of $2.6 million during Q4 2022.
  • Its 4-year average for Liabilities and Shareholders Equity is $97.9 million, with a median of $10.4 million in 2025.
  • The largest annual percentage gain for Envoy Medical's Liabilities and Shareholders Equity in the last 5 years was 22359.15% (2023), contrasted with its biggest fall of 9504.1% (2023).
  • Over the past 4 years, Envoy Medical's Liabilities and Shareholders Equity (Quarter) stood at $2.6 million in 2022, then surged by 223.59% to $8.3 million in 2023, then soared by 39.5% to $11.5 million in 2024, then decreased by 29.1% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $9.9 million for Q2 2025, and $10.4 million during Q1 2025.